相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma
Jingwen Li et al.
JOURNAL OF CANCER (2022)
Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope
Adva Mechaly et al.
ANTIBODIES (2022)
A review of glioblastoma immunotherapy
Ravi Medikonda et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
Mohammad Heiat et al.
TOXINS (2021)
DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study
Hamid Hashemi Yeganeh et al.
TOXINS (2021)
Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin
Seyed Mehdi Havaei et al.
FRONTIERS IN ONCOLOGY (2021)
Antibody-Based Immunotoxins for Colorectal Cancer Therapy
Laura Sanz et al.
BIOMEDICINES (2021)
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D. Fleming et al.
HEPATOLOGY (2020)
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
Dipongkor Saha et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
Xin Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
Fiona A. Desland et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Construction of an immunized rabbit phage display antibody library for screening microcystin-LR high sensitive single-chain antibody
Chongxin Xu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2019)
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
Vidyalakshmi Chandramohan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
Christopher B. Jackson et al.
CANCER RESEARCH (2019)
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Ryan C. Gimple et al.
GENES & DEVELOPMENT (2019)
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Bryan D. Choi et al.
CLINICAL CANCER RESEARCH (2019)
Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models
Yasmin Leshem et al.
TOXINS (2019)
The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials
Maryam Moradi Binabaj et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
Xiaoyue Chen et al.
NATURE COMMUNICATIONS (2018)
The 2016 World Health Organization classification of tumours of the central nervous system
Chiara Villa et al.
PRESSE MEDICALE (2018)
Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo
Ronit Mazor et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications
Alba A. Brandes et al.
ONCOLOGIST (2017)
K Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
Gilad Kaplan et al.
TOXINS (2016)
Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis
Wei Gao et al.
NATURE COMMUNICATIONS (2015)
Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
Emily Mason-Osann et al.
SCIENTIFIC REPORTS (2015)
Glioblastoma: From Molecular Pathology to Targeted Treatment
Timothy F. Cloughesy et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
Toxin-Based Targeted Therapy for Malignant Brain Tumors
Vidyalakshmi Chandramohan et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma
Elana S. Tykocinski et al.
NEURO-ONCOLOGY (2012)
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
Hui Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Temozolomide: Mechanisms of Action, Repair and Resistance
Jihong Zhang et al.
Current Molecular Pharmacology (2011)
Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
John E. Weldon et al.
BLOOD (2009)
Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients
Kan V. Lu et al.
CANCER RESEARCH (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Gaspar J. Kitange et al.
NEURO-ONCOLOGY (2009)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The natural history of EGFR and EGFRvIII in glioblastoma patients
AB Heimberger et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
AA Jungbluth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
